Clinical Scorecard: A Suprachoroidal Route to Retinal Therapy

At a Glance

Key Highlights

• Suprachoroidal delivery shows durable effects and fewer complications compared to traditional methods.
• ABBV-RGX-314 demonstrated significant improvement in DRSS scores in NPDR patients.
• AAVIATE trial showed marked reduction in anti-VEGF injection rates across dose cohorts.
• SCS Microinjector is the primary device used for suprachoroidal injections.
• Potential for reducing treatment burden and increasing accessibility.

Guideline-Based Recommendations

Diagnosis

• Assess severity of diabetic retinopathy using the Diabetic Retinopathy Severity Scale (DRSS).
• Monitor for vision-threatening complications.

Management

• Consider suprachoroidal gene therapy for NPDR and nAMD.
• Utilize SCS Microinjector for administration.

Monitoring & Follow-up

• Regular follow-up to evaluate treatment efficacy and monitor for adverse events.

Risks

• Potential for mild to moderate ocular adverse events, generally responsive to topical corticosteroids.

Patient & Prescribing Data

Patients with nonproliferative diabetic retinopathy and neovascular age-related macular degeneration.

Single suprachoroidal injection of ABBV-RGX-314 has shown promising results in improving DRSS and reducing treatment frequency.

Clinical Best Practices

• Prioritize patient education on the benefits and risks of suprachoroidal gene therapy.
• Ensure proper training for healthcare providers on the use of the SCS Microinjector.
• Monitor patients closely for treatment response and adverse effects.

References

• 2025 Retina World Congress Presentation by David S. Boyer, MD